1-methyl-1H-indole-5-sulfonyl chloride → 5-(3,4-Dimethoxyphenyl)-4,4-dimethyl-2-{1-[(1-methyl-1H-indol-5-yl)sulfonyl]piperidin-4-yl}-2,4-dihydro-3H-pyrazol-3-one

HRID 1914165

반응식

HRID 1914165 반응식
Cl.[CH3:2][O:3][C:4]1[CH:5]=[C:6]([C:12]2[C:13]([CH3:25])([CH3:24])[C:14](=[O:23])[N:15]([CH:17]3[CH2:22][CH2:21][NH:20][CH2:19][CH2:18]3)[N:16]=2)[CH:7]=[CH:8][C:9]=1[O:10][CH3:11].[CH3:26][N:27]1[C:35]2[C:30](=[CH:31][C:32]([S:36](Cl)(=[O:38])=[O:37])=[CH:33][CH:34]=2)[CH:29]=[CH:28]1>>[CH3:2][O:3][C:4]1[CH:5]=[C:6]([C:12]2[C:13]([CH3:25])([CH3:24])[C:14](=[O:23])[N:15]([CH:17]3[CH2:22][CH2:21][N:20]([S:36]([C:32]4[CH:31]=[C:30]5[C:35](=[CH:34][CH:33]=4)[N:27]([CH3:26])[CH:28]=[CH:29]5)(=[O:37])=[O:38])[CH2:19][CH2:18]3)[N:16]=2)[CH:7]=[CH:8][C:9]=1[O:10][CH3:11]

참가 물질

3

반응물 2

HCID 185257511-methyl-1H-indole-5-sulfonyl chlorideHCID 666164065-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-piperidin-4-yl-2,4-dihydro-3H-pyrazol-3-one hydrochloride2회

생성물 1

HCID 673644645-(3,4-Dimethoxyphenyl)-4,4-dimethyl-2-{1-[(1-methyl-1H-indol-5-yl)sulfonyl]piperidin-4-yl}-2,4-dihydro-3H-pyrazol-3-one

실험 절차

The title compound is prepared analogously as described for GP1 using 5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-(piperidin-4-yl)-2,4-dihydro-3H-pyrazol-3-one (compound B1) and 1-methyl-1H-indole-5-sulfonyl chloride as starting compounds. The crude product is purified by crystallization from EA and diethyl ether to yield the title compound.

후처리

  1. customThe title compound is prepared analogously
  2. customThe crude product is purified by crystallization from EA and diethyl ether

출처 및 근거

ORD 기록
ord-7c0cb770244f44a7b1f206b48e4e12c9
출처 데이터셋
uspto-grants-2013_12
특허 번호
US08609848B2

연결된 노트

불러오는 중…